Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.

Edward J GaneHyung Joon KimKumar VisvanathanYoon Jun KimAnh-Hoa NguyenJeffrey J WallinDiana Y ChenCirce McDonaldPriyanka AroraSusanna K TanAnuj GaggarStuart K RobertsYoung Suk Lim

Published in: Hepatology (Baltimore, Md.) (2021)

Selgantolimod was safe and well-tolerated in virally suppressed and viremic patients with CHB and elicited cytokine responses consistent with target engagement. Further studies with longer durations of selgantolimod treatment are required to evaluate efficacy.

Keyphrases

hepatitis b virus
toll like receptor
immune response
social media
combination therapy
liver fibrosis
nuclear factor